Cellectgen, Inc

BCN Biosciences LLC is a research-focused company located in Pasadena, California, specializing in innovative bioscience solutions. The company operates a research lab dedicated to advancing scientific knowledge and technology in the field. With a commitment to collaboration and development, BCN Biosciences engages in various partnerships to enhance its research capabilities. The team is dedicated to providing cutting-edge products and services that contribute to the biosciences industry. Generated from the website

De Novo Software, based in Pasadena, CA, specializes in providing advanced flow cytometry data analysis solutions through its flagship product, FCS Express. Trusted by thousands of researchers globally, the software bridges the gap between complex raw data and clear, presentation-ready results, making it a preferred choice for both academic and clinical laboratories. Recently acquired by Siemens Digital Industries Software, De Novo Software emphasizes user-friendly design that integrates seamlessly with familiar Microsoft Office tools. This approach enables researchers and clinicians to efficiently analyze and communicate results, while also offering exceptional technical support to enhance their workflow and improve analysis quality. Generated from the website

Genervon Biopharmaceuticals is a clinical-stage biopharmaceutical company based in Pasadena, CA, dedicated to pioneering innovative approaches to drug development for complex neurological disorders. With a focus on multi-target drug development, the company has synthesized GM6, a peptide that passes through the blood-brain barrier, aiming to improve clinical outcomes for conditions such as ALS, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. For over twenty years, Genervon has been committed to research and development in the pursuit of curative therapies for neurodegenerative diseases, utilizing a master regulatory approach to address the common underlying pathophysiology of these disorders. The company is actively seeking partners to advance GM6 from its development phase into a marketable therapy for patients in need. Generated from the website